Literature DB >> 21036247

Assessment of CK2 constitutive activity in cancer cells.

Maria Ruzzene1, Giovanni Di Maira, Kendra Tosoni, Lorenzo A Pinna.   

Abstract

At variance with the great majority of protein kinases that become active only in response to specific stimuli and whose implication in tumors is caused by genetic alterations conferring to them unscheduled activity, the highly pleiotropic Ser/Thr-specific protein kinase CK2 is constitutively active even under normal conditions and no gain-of-function CK2 mutants are known. Nevertheless, CK2 level is abnormally high in cancer cells where it is believed to generate an environment favorable to the development of malignancy, through a mechanism denoted as "non-oncogene addiction." This makes CK2 not only an appealing target to counteract different kinds of tumors but also a valuable marker of cells predisposed to undergo neoplastic transformation owing to the presence in them of CK2 level exceeding a critical threshold. Such a prognostic exploitation of CK2 would imply the availability of methods suitable for the reliable, sensitive, and specific quantification of its activity in biological samples and in living cells. The aim of this chapter is to describe a number of procedures applicable to the quantitative determination of CK2 activity and to provide experimental details designed for rendering these assays as sensitive and selective as possible even in the presence of many other protein kinases. The procedures described roughly fall in three categories: (i) in vitro quantification of CK2 activity in crude biological samples and cell lysates; (ii) in-cell assay of endogenous CK2 activity based on the phosphorylation of reporter substrates; (iii) identification of CK2 targets in malignant and normal cells.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21036247     DOI: 10.1016/B978-0-12-381298-8.00024-1

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  24 in total

1.  Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.

Authors:  Christian Borgo; Luca Cesaro; Valentina Salizzato; Maria Ruzzene; Maria Lina Massimino; Lorenzo A Pinna; Arianna Donella-Deana
Journal:  Mol Oncol       Date:  2013-08-22       Impact factor: 6.603

2.  The p23 co-chaperone protein is a novel substrate of CK2 in Arabidopsis.

Authors:  Kendra Tosoni; Alex Costa; Stefania Sarno; Stefano D'Alessandro; Francesca Sparla; Lorenzo A Pinna; Michela Zottini; Maria Ruzzene
Journal:  Mol Cell Biochem       Date:  2011-07-07       Impact factor: 3.396

3.  Protein kinase CK2 accumulation in "oncophilic" cells: causes and effects.

Authors:  Maria Ruzzene; Kendra Tosoni; Sofia Zanin; Luca Cesaro; Lorenzo A Pinna
Journal:  Mol Cell Biochem       Date:  2011-07-07       Impact factor: 3.396

4.  Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential.

Authors:  Giorgio Cozza; Cristina Girardi; Alessandro Ranchio; Graziano Lolli; Stefania Sarno; Andrzej Orzeszko; Zygmunt Kazimierczuk; Roberto Battistutta; Maria Ruzzene; Lorenzo A Pinna
Journal:  Cell Mol Life Sci       Date:  2014-01-18       Impact factor: 9.261

Review 5.  Fragile X-related protein family: a double-edged sword in neurodevelopmental disorders and cancer.

Authors:  Mrinmoyee Majumder; Roger H Johnson; Viswanathan Palanisamy
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-09-02       Impact factor: 8.250

6.  Phosphoproteomics Identifies CK2 as a Negative Regulator of Beige Adipocyte Thermogenesis and Energy Expenditure.

Authors:  Kosaku Shinoda; Kana Ohyama; Yutaka Hasegawa; Hsin-Yi Chang; Mayu Ogura; Ayaka Sato; Haemin Hong; Takashi Hosono; Louis Z Sharp; David W Scheel; Mark Graham; Yasushi Ishihama; Shingo Kajimura
Journal:  Cell Metab       Date:  2015-11-08       Impact factor: 27.287

Review 7.  Post-translational modifications of the Fragile X Mental Retardation Protein in neuronal function and dysfunction.

Authors:  Marta Prieto; Alessandra Folci; Stéphane Martin
Journal:  Mol Psychiatry       Date:  2019-12-10       Impact factor: 15.992

8.  Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells.

Authors:  Sofia Zanin; Christian Borgo; Cristina Girardi; Sean E O'Brien; Yoshihiko Miyata; Lorenzo A Pinna; Arianna Donella-Deana; Maria Ruzzene
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

9.  Occludin S408 phosphorylation regulates tight junction protein interactions and barrier function.

Authors:  David R Raleigh; Devin M Boe; Dan Yu; Christopher R Weber; Amanda M Marchiando; Emily M Bradford; Yingmin Wang; Licheng Wu; Eveline E Schneeberger; Le Shen; Jerrold R Turner
Journal:  J Cell Biol       Date:  2011-05-02       Impact factor: 10.539

10.  Activation of protein kinase CK2 attenuates FOXO3a functioning in a PML-dependent manner: implications in human prostate cancer.

Authors:  A Chatterjee; U Chatterjee; M K Ghosh
Journal:  Cell Death Dis       Date:  2013-03-14       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.